Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR

Completed · Phase 2 · Has a placebo group

Conditions studied: Seasonal Allergic Rhinitis, Hayfever

In brief

This is a phase 2, randomized, double-blind, placebo-controlled, parallel-group, 2-week, multi-center, dose-range-finding study in male or female patients (12 years and older) with SAR.

Key facts

Study ID
NCT00854360
Run by
Teva Branded Pharmaceutical Products R&D, Inc.
People needed
487
Starts
2009-03-01
Expected to finish
2009-05-01
Last updated by the study team
2012-05-22

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.